Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study

Peer Review reports

Original Submission
28 Sep 2015	Submitted	Original manuscript
16 Jan 2016	Reviewed	Reviewer Report - Jaw-Yuan Wang
18 Jan 2016	Reviewed	Reviewer Report - Xiaoqing Wu
12 Feb 2016	Author responded	Author comments - KUN-HUEI YEH
Resubmission - Version 2
12 Feb 2016	Submitted	Manuscript version 2
5 Apr 2016	Author responded	Author comments - KUN-HUEI YEH
Resubmission - Version 3
5 Apr 2016	Submitted	Manuscript version 3
Publishing
11 May 2016	Editorially accepted
24 May 2016	Article published	10.1186/s12885-016-2358-2

Back to article page